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Abstract 38 
 39 
Objectives:  40 
The accepted treatment for acute limb ischemia (ALI) is immediate systemic anticoagulation and 41 
timely reperfusion to restore blood flow.  In this study, we describe the retrospective assessment of 42 
pretransfer management decisions by referring hospitals to an academic tertiary care facility and its 43 
impact on perioperative adverse events. 44 
 45 
Methods:  46 
A retrospective analysis of ALI patients transferred to us via our Level I Vascular Emergency 47 
program from 2010 to 2013 was performed.  Patient demographics, comorbidities, Rutherford ischemia 48 
classification, time to anticoagulation, and time to reperfusion were tabulated and analyzed for correlation 49 
to incidence of major adverse limb events (MALE), mortality, and bypass patency in the perioperative 50 
period (30-day postoperative).  All time intervals were calculated from the onset of symptoms and 51 
categorized into three subcohorts (<6 hrs, 6-48 hrs, and >48 hrs).    52 
 53 
Results:  54 
Eighty-seven patients with an average age of 64.0 (± 16.2) years presented to outlying hospitals 55 
and was transferred to us with lower extremity ALI.  The mean delay from symptom onset to initial 56 
referring physician evaluation was 18.3 hrs.  At that time of evaluation, 53.8% had Rutherford class IIA 57 
ischemia and 36.3% had class IIB ischemia.  Seventy-six (87.4%) patients were started on heparin 58 
previous to transfer.  However, only 44 (57.9%) patients reached therapeutic levels as measured by 59 
activated partial thromboplastin time (aPTT) prior to definitive revascularization.  A delay of 60 
anticoagulation initiation >48 hrs from symptom onset was associated with increased 30-day 61 
reintervention rates compared with the <6 hrs group (66.7% vs. 23.5%; p<0.05).  However, time to 62 
reperfusion had no statistically significant impact on MALE, 30-day mortality, or 30-day interventional 63 
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patency in our small cohorts.  Additionally, patients with a previous revascularization had a higher 30-day 64 
reintervention rate (46.5%; p<0.05).        65 
 66 
Conclusions:  67 
The practice of timely therapeutic anticoagulation of patients referred for ALI from community 68 
facilities occurs less frequently than expected and is associated with an increased perioperative 69 
reintervention rate.  70 
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Background 71 
 72 
Paramount to the treatment of ALI is prompt diagnosis, anticoagulation, and timely 73 
revascularization to minimize the risk of limb loss.1  Unfortunately, delays in diagnosis and treatment 74 
continue to be a significant challenge, especially in those who are initially evaluated at a community 75 
hospital without dedicated vascular specialists.2  Our Level I Vascular Emergency program was initiated 76 
in 2009 as part of an effort to improve vascular outcomes in the State of Indiana.  Transferring facilities 77 
state the diagnosis, hospital location, and urgency of pathology.  All patients stable enough for transfer 78 
are accepted, and transportation is accomplished by ground or air at the discretion of the accepting 79 
physician and weather conditions.   80 
 81 
Although revascularization strategies and outcomes are well studied, there is a relative dearth of 82 
knowledge regarding the effect of preintervention anticoagulation with timely triage and their effects on 83 
limb salvage and mortality.3  Therefore, the purpose of this study was to review our three-year 84 
experience, immediately after initiation of the Level I program, with the pretransfer care of ALI patients 85 
at our tertiary referral center and the outcomes associated with deviations from defined ideal 86 
management.  87 
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Methods 88 
 89 
After approval from the Indiana University Institutional Review Board (IRB), we performed a 90 
retrospective analysis of a prospectively maintained database of all patients diagnosed with ALI 91 
transferred to our facility via our Level I program from Jan 2010 to August 2013.  For purposes of this 92 
study, ALI was defined as a cold, painful, ischemic limb presenting within a week of symptom onset.4,5   93 
 94 
Patient demographics, comorbidities, Rutherford ischemia severity, time to heparinization, time 95 
to revascularization, and postoperative outcomes were abstracted via review of medical records.  Times to 96 
emergency room (ER) presentation, heparin initiation, and revascularization were all recorded from the 97 
time of symptom onset and arbitrarily categorized into three subgroups (<6 hrs, 6-48 hrs, and >48 hrs).  98 
Our 30-day outcomes of interest were major amputation (above ankle), interventional patency, need for 99 
vascular reinterventions, and mortality.  Categorical variables were compared with Fisher’s exact tests 100 
while continuous variables (± standard deviation) were compared with Student’s T-tests at an α of 0.05. 101 
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Results 102 
 103 
Comorbidities 104 
 105 
In the three years queried, 103 patients with limb ischemia were transferred to us as a Level I 106 
Vascular Emergency; patients presenting with upper limb ischemia were excluded leaving 87 remaining 107 
cases.  Demographics and comorbidities of the study population are detailed in Table 1.  The average age 108 
of our population was 64.5 (± 16.2) years with a slight predisposition towards the male gender (57.5%).  109 
The most common comorbidity in this population was CAD (70.7%).  Atrial fibrillation, a frequent 110 
source of thromboembolism to the extremities, was present in 20.1% of subjects.  Additionally, 39.0% of 111 
the patients had a previous history of ipsilateral vascular bypass and 40.2% were actively smoking at the 112 
time of ALI onset. 113 
 114 
Preinterventional Management 115 
 116 
The mean duration of time from symptom onset to initial outside hospital (OSH) evaluation was 117 
18.3 hrs (range = 1-118 hrs, median = 6 hrs).  At the time of evaluation by the first physician, 53.8% had 118 
Rutherford class IIA ischemia and 36.3% had class IIB ischemia.  The average delay from initial OSH 119 
evaluation to evaluation by a tertiary care hospital physician was 3.0 hrs (median = 2.0 hrs).  After arrival 120 
to our facility from a mean transfer distance of 48.0 miles (range 1-183 = miles, median = 47 miles), 121 
mean delay until definitive blood flow restoration was 9.5 hrs (median = 5.0 hrs).   122 
 123 
Among the 76 (87.4%) patients who received systemic heparin previous to transfer, only 44 124 
(57.9%) reached a documented therapeutic aPTT before their operation (Table 2).  Of the remaining 125 
anticoagulated patients, 13 maintained nontherapeutic aPTTs while 19 patients did not have an aPTT 126 
measured before revascularization.  Of those without a documented aPTT, 89.5% presented emergently 127 
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for IIB ischemia and had intraoperative activated clotting times (ACT) on record.  Of note, only 10 128 
(11.5%) patients received heparin and were documented therapeutic by aPTT in less than 6 hrs from 129 
symptom onset.  Eleven (12.6%) patients were not anticoagulated at all after presentation to the 130 
transferring facility.  The reasons for not starting anticoagulation were unclear in all cases; however, two 131 
patients clearly did not have a salvageable limb.  There were no differences between patients with IIA and 132 
IIB ischemia in terms of delays to heparin initiation (p=0.25) or revascularization (p=0.47).   133 
 134 
Intervention 135 
 Arterial flow was restored in only three (3.4%) patients via a completely percutaneous approach.  136 
All three patients were in IIA ischemia at presentation and consisted of one with an acutely thrombosed 137 
PTFE graft who was thrombolysed and two occlusions of the iliac and superficial femoral arteries treated 138 
by angioplasty and stenting.  The remaining revascularizations utilized a primarily open technique.  Of 139 
these patients, 50 (59.5%) required primary thromboembolectomy while 28 (33.3%) patients required a de 140 
novo lower extremity vascular bypass.  Only 12.6% of the total study population was revascularized 141 
within 6 hrs of symptom onset.  However, in the IIB ischemia subcohort, 36.3% was revascularized 142 
within 6 hrs of symptom onset.     143 
 144 
30-day Major Adverse Events 145 
 146 
Major Amputations: 147 
The 30-day major amputation rate for all transferred ALI patients was 13.1% (Table 3).  Time to 148 
anticoagulation did not affect amputation risk.  We did not observe a difference between Rutherford IIA 149 
and IIB patients (p=0.43); however, both groups experienced a lower amputation rate compared to those 150 
presenting with class III ischemia (p<0.01).  A history of an ipsilateral revascularization did not influence 151 
amputation risk (p=0.49).  Delays to therapeutic aPTT and revascularization did not influence 152 
perioperative major amputation rates in our population. 153 
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 154 
Reinterventions: 155 
The overall 30-day vascular reintervention rate was 36.8%.  We observed a difference in 156 
reintervention based on time to systemic heparinization with the >48 hrs cohort experiencing a 66.7% 157 
event rate compared to a 23.5% in patients heparinized in <6 hrs (p<0.05).  Patients who had a previous 158 
ipsilateral revascularization were at a higher risk of reintervention (46.7% vs 36.8%, p<0.05).  No 159 
difference was observed between class IIA and IIB ischemia patients.  Those who delayed ER 160 
presentation (>48 hrs) also were at greater risk for perioperative reintervention (p<0.05).  Delays until 161 
therapeutic aPTT and revascularization did not influence perioperative vascular reintervention risk. 162 
 163 
Patency: 164 
The overall 30-day interventional patency rate was 72.2%.  There was no difference based on 165 
delay to heparinization; although, a nonsignificant inferior patency rate was noted in the >48 hrs cohort 166 
compared to the minimal delay cohort (60% vs 76.5%, p=0.42).  Additionally, we observed no difference 167 
between class IIA and IIB patients.  There was also no difference based on delay to ER presentation or 168 
presence of previous ipsilateral bypass.  Delays until therapeutic aPTT and revascularization did not 169 
influence perioperative patency.  170 
 171 
Mortality:  172 
The overall 30-day mortality was 7.9%.  The most common cause of death was septic shock 173 
(n=3) followed by myocardial infarction (n=1), multiorgan systems failure (n=1), and acute mesenteric 174 
ischemia (n=1).  While there was no statistical difference in mortality by time to anticoagulation, a trend 175 
was observed.  All patients who were heparinized without delay survived, compared to a 10.0% mortality 176 
(p=0.28) in the 6-48 hrs group and 13.3% (p=0.20) in the >48 hrs group.  The degree of Rutherford 177 
ischemia did not seem to affect perioperative mortality in our population.  Similarly, delays until 178 
therapeutic aPTT and revascularization did not influence perioperative mortality.  179 
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Discussion 180 
 181 
In ALI, a sudden cessation of arterial blood flow directly blocks nerve, soft tissue, and 182 
musculoskeletal access to resources vital to cell survival.6  In this setting, a patient has approximately six 183 
hours for restoration of blood carrying oxygen and nutrients before irreversible functional damage 184 
occurs.7  However, the duration until irreversible damage is dependent on tissue conditioning and degree 185 
of collateralization from preexisting baseline vascular disease.8  Therefore, clinical scoring systems are 186 
utilized to predict disease severity to guide treatment individualization.9  Of particular importance is the 187 
Rutherford ALI categorization system, an easy to use clinical tool which classifies ischemia severity and 188 
guides urgency to revascularization.5   189 
 190 
The latest ALI consensus practice guideline was developed in conjunction with the Society of 191 
Vascular Surgery, American Heart Association, Intersociety Consensus for the Management of Peripheral 192 
Arterial Disease, and representative bodies of cardiology, radiology, and vascular medicine.  In these 193 
guidelines, only four level I recommendations pertain to the preoperative care of the ALI patient 194 
(Figure).10  At the time of presentation to any facility, patients suspected of ALI should be evaluated by 195 
an experienced clinician comfortable with the assessment of limb viability and can implement immediate 196 
medical therapy.  At that time, a comprehensive history should be taken to determine the cause of 197 
thrombosis or embolization.  Additionally, the initial evaluation should focus on the rapid assessment of 198 
1) limb viability and 2) potential for salvage.  It is key to note that this assessment does not require 199 
imaging, especially if it may delay appropriate triage.  After diagnosis, prompt systemic anticoagulation 200 
should be initiated unless a hard contraindication is present.11  201 
 202 
The use of any antiplatelet and/or anticoagulant must be communicated clearly and concisely by 203 
the transferring team.  Especially important details to include are time of medication initiation and dose.  204 
In our review, 13 patients received heparin without documentation of initiation time by the transferring 205 
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team.  Additionally, 11 patients did not receive heparin at the transferring facility at all.  While two limbs 206 
were clearly nonsalvageable, none of these 11 patients had a clear contraindication on retrospective chart 207 
review.  While a possible explanation may be an attempt to avoid coagulopathy during surgery by 208 
clinicians uncomfortable with preoperative anticoagulation, the short half-life of unfractionated heparin 209 
makes cessation of medication administration on the way to the OR an ideal therapeutic plan.12  We 210 
observed a trend of increasing mortality in those who had a delay until systemic heparinization.  This 211 
effect may prove to be significant with a higher-powered study.  Failure to anticoagulate in the ALI 212 
population is not an isolated problem for our facility; an European experience reported by Spanos et al 213 
reported their four-year experience of 112 consecutive ALI patients and found that only 67% of them 214 
were anticoagulated at the time of arrival after transfer.13  A concerted effort should be made to 215 
emphasize the importance of prompt anticoagulation to our transferring colleagues.  216 
 217 
The superior outcomes observed in ALI patients who received timely anticoagulation occurred 218 
regardless of their aPTT status in our study, thus underscoring the importance of anticoagulation and less 219 
so the emphasis on clotting times in limb salvage.  We did not observe a significant difference in 220 
outcomes with regards to perioperative mortality, patency, and major amputation in those who had a >48 221 
hr delay to heparinization.  However, this was almost certainly due to lack of power as clinical experience 222 
would dictate a morbid clinical course in these patients.  Unless contraindicated, the best anticoagulant in 223 
the acute setting is IV unfractionated heparin.14  The dosing of which is discussed in detail elsewhere.15  224 
Despite limitations, aPTT remains the most convenient and frequently used method for monitoring in vivo 225 
heparin response.  It should be measured minutes after initial medication bolus to confirm therapeutic 226 
effect and continuously monitored to gauge needed changes to the continuous rate.16   227 
 228 
A problem we encountered in our cohort was a significant delay in presentation to the initial 229 
hospital of more than 18 hours from symptom onset.  The worst offenders were those with baseline 230 
disease and therefore assumed acute limb pain was a day-to-day variant of symptoms and not a sudden 231 
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progression of disease.  This incorrect assumption often made a difference between the salvage of a 232 
functional limb or not.  Therefore, the burden is on us, as vascular surgeons, to educate our patients on 233 
signs of ischemic progression from chronic disease to ALI in the office setting before it occurs.  234 
 235 
Seven patients (8%) were transferred without documentation of a lower extremity pulse exam in 236 
the history and physical of the initial evaluating physician.  Not only is this a clinical concern, but it may 237 
have serious medicolegal ramifications.  A detailed lower extremity vascular exam is standard of care for 238 
any patient with limb pain, sensory loss, or motor dysfunction.17  Although the pulse exam may be 239 
subjective, the following classification is recommended at minimum: a) normal, b) weakly palpable, c) 240 
doppler signal present, and d) no signal.18  The status of the dorsalis pedis and posterior tibial arteries on 241 
both sides need to be documented in the medical record.   242 
 243 
As is the case for any retrospective review, this study has some inherent limitations.19  However, 244 
a recurring deficit which developed during data collection was the incomplete documentation from the 245 
transferring facilities on time of symptom onset, degree of ischemia, and time and effect of 246 
anticoagulation despite receiving all available medical records.  Consequently, the patient pool for 247 
statistical analysis was reduced affecting the power to detect outcome differences.  Although we did 248 
receive direct transfers from community vascular surgeons, most of the patients arrived from ERs staffed 249 
by emergency, family, and internal medicine specialists often uncomfortable with ALI management.  As 250 
such, it is of upmost importance that the accepting physician clearly state to the transferring physician the 251 
treatment plan before, during, and after the transfer process.    252 
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Conclusion 253 
 254 
ALI is a challenging pathology for the vascular surgeon.  In many regions, referral of those 255 
diagnosed at community hospitals to tertiary centers have become the established system.  In this study, 256 
we report inferior perioperative outcomes associated with patients who did not receive treatment per ALI 257 
practice guidelines.  Therefore, improved system-wide protocols in the diagnosis, care, and transfer of 258 
these patients are needed to provide safe, timely care.  259 
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Legends 
 
Table 1 
Demographics and comorbidities 
 
Table 2 
Delays in treatment 
 
Table 3 
Perioperative outcomes by delay until heparinization from symptom onset.  Fisher’s exact testing was 
performed comparing the minimally delayed cohort (<6 hrs) to the remaining groups. 
 
 
Figure 
Summary of the latest AHA/ACC consensus practice guidelines  
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Condition Incidence
Age 64.5 ± 16.2
Male 57.5%
CAD 70.7%
HTN 67.9%
Active Smoker 40.2%
HLD 37.8%
DM 32.1%
AF 20.1%
COPD 18.3%
Previous Ipsilateral Revascularization 39.0%
Rutherford Classification at Presentation Incidence
I 7.5%
IIA 53.8%
IIB 36.3%
III 2.5%
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Delay to ER Presentation (n=87) Incidence
<6 hrs 37.9%
6-48 hrs 25.3%
>48 hrs 16.1%
Unknown 20.7%
Delay to Heparin (n=76) Incidence
<6 hrs 23.7%
6-48 hrs 39.5%
>48 hrs 19.7%
Unknown 17.1%
Delay to Revascularization (n=71) Incidence
<6 hrs 12.7%
6-48 hrs 69.0%
>48 hrs 18.3%
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<6hr 6-48hr >48hr
30-day Amputation 16.7% 6.9% 21.4%
p=0.36 p=1.0
30-day Reintervention 23.5% 32.2% 66.7%
p=0.74 p=0.03
30-day Mortality 0% 10.0% 13.3%
p=0.28 p=0.20
30-day Patency 76.5% 74.1% 60%
p=1.0 p=0.42
Delay Until Systemic Heparinization
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Patients suspected of ALI should be 
emergently evaluated by a clinician with 
sufficient experience to determine limb 
viability and implement appropriate therapy 
A comprehensive history 
should be obtained to 
determine the cause of 
thrombosis and/or embolization
The initial evaluation should 
determine 1) limb viability and 
2) potential for salvage – it 
does not require imaging
Systemic anticoagulation 
should be initiated 
immediately, unless a hard 
contraindication is present
Tenet 2Tenet 1 Tenet 3 Tenet 4
Patient Suspected of ALI
